Watch our event with BioIDEA: Biotech vs COVID-19

May 28, 2020 | News | 0 comments

Daniel Gigante

BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.

The event was fantastic. Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A Pharmaceuticals, Ed Painter, Chairman and CIO of A2A Pharmaceuticals; Peter Leonardi, CEO and Founder of OmniCyte; and our very own Andrew Satz, CEO and Co-Founder of EVQLV.

Watch the event below.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

NY Bio-Computation Startup EVQLV Closes Financing Round

by | February 8, 2021 | Press Releases | 0 Comments

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...
Read More

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

by | February 1, 2021 | News | 0 Comments

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...
Read More

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

by | January 12, 2021 | Press Releases | 0 Comments

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...
Read More

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

by | December 16, 2020 | Press Releases | 0 Comments

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...
Read More

EVQLV Accepted to Prestigious Techstars Boston Accelerator

by | November 18, 2020 | News | 0 Comments

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...
Read More

Pin It on Pinterest